Association of Lifetime Cognitive Engagement and Low β-Amyloid Deposition

Susan M. Landau, PhD; Shawn M. Marks, BS; Elizabeth C. Mormino, PhD; Gil D. Rabinovici, MD; Hwamee Oh, PhD; James P. O’Neil, PhD; Robert S. Wilson, PhD; William J. Jagust, MD

Objective: To assess the association between lifestyle practices (cognitive and physical activity) and β-amyloid deposition, measured with positron emission tomography using carbon 11–labeled Pittsburgh Compound B ([11C]PiB), in healthy older individuals.

Design: Cross-sectional clinical study.

Setting: Berkeley, California.

Participants: Volunteer sample of 65 healthy older individuals (mean age, 76.1 years), 10 patients with Alzheimer disease (AD) (mean age, 74.8 years), and 11 young controls (mean age, 24.5 years) were studied from October 31, 2005, to February 22, 2011.

Main Outcome Measures: Cortical [11C]PiB average (frontal, parietal, lateral temporal, and cingulate regions) and retrospective, self-report scales assessing participation in cognitive activities (eg, reading, writing, and playing games) and physical exercise.

Results: Greater participation in cognitively stimulating activities across the lifespan, but particularly in early and middle life, was associated with reduced [11C]PiB uptake (P < .001, accounting for age, sex, and years of education). Older participants in the highest cognitive activity tertile had [11C]PiB uptake comparable to young controls, whereas those in the lowest cognitive activity tertile had [11C]PiB uptake comparable to patients with AD. Although greater cognitive activity was associated with greater physical exercise, exercise was not associated with [11C]PiB uptake.

Conclusions: Individuals with greater early- and middle-life cognitive activity had lower [11C]PiB uptake. The tendency to participate in cognitively stimulating activities is likely related to engagement in a variety of lifestyle practices that have been implicated in other studies showing reduced risk of AD-related pathology. We report a direct association between cognitive activity and [11C]PiB uptake, suggesting that lifestyle factors found in individuals with high cognitive engagement may prevent or slow deposition of β-amyloid, perhaps influencing the onset and progression of AD.


The recent development of the radiopharmaceutical carbon 11–labeled Pittsburgh Compound B ([11C]PiB) has made it possible to image fibrillar forms of the β-amyloid (Aβ) protein, which is the major constituent of the amyloid plaque in Alzheimer disease (AD). Studies applying this technique have demonstrated [11C]PiB accumulation throughout cortex in most patients with AD. More important, 20% to 30% of healthy, cognitively normal older individuals also display significant PiB uptake, which is consistent with evidence that some older individuals who were cognitively intact during life show substantial numbers of Aβ plaques post mortem. Greater understanding of the factors associated with Aβ variability in the healthy older population could have important consequences for disease prevention.

Recent evidence indicates that lifestyle practices, such as increased physical exercise, are associated with reduced Aβ deposition based on [11C]PiB positron emission tomography (PET) and cerebrospinal fluid Aβ42 measurements. Participation in cognitively stimulating activities has also been linked to reduced risk of late-life cognitive decline and AD. An individual’s tendency to engage in physically and cognitively stimulating activities is likely related to a broad set of lifestyle factors that are difficult to quantify but include occupational, social, community, and recreational practices. We assessed engagement in cognitive and physical activities and hypothesized that greater levels of engagement may be associated with less Aβ later in life.

We investigated this hypothesis by performing [11C]PiB PET and neuropsychological testing in a sample of cognitively

Author Affiliations: Helen Wills Neuroscience Institute (Drs Landau, Mormino, Rabinovici, Oh, and Jagust and Mr Marks) and School of Public Health (Dr Jagust), University of California, Berkeley, and Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California (Drs Landau, Rabinovici, O’Neil, and Jagust); Memory and Aging Center and Department of Neurology, University of California, San Francisco (Dr Rabinovici); and Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Illinois (Dr Wilson).
normal older participants. Aβ deposition, characterized as mean cortical [11C]PiB PET uptake, was examined in healthy older participants and comparison samples of young participants and patients with AD. A variety of neuropsychological and lifestyle measurements were also obtained and assessed in relation to Aβ deposition for healthy older participants only, including frequency of engagement in cognitively demanding activities, frequency of engagement in physical and leisure activities, and current episodic memory function.

METHODS

STUDY PARTICIPANTS

Sixty-five cognitively normal older participants (mean ± SD age, 76.1 ± 6.3 years) were recruited from the Berkeley, California, community (via newspaper advertisements, flyers, and public lectures and events) and enrolled in the ongoing Berkeley Aging Cohort, which assesses individuals at an approximately yearly interval. During this assessment, participants completed an extensive neuropsychological battery. For participants who had completed more than 1 neuropsychological evaluation, only data obtained during the evaluation closest to the imaging sessions were used in this study. Inclusion criteria were age of 50 years or older, Mini-Mental State Examination (MMSE) score of 26 or higher,9 living independently in the community, and normal performance on cognitive tests (≥2 SDs below age-, years of education-, and sex-adjusted means). Exclusion criteria included major neurologic, psychiatric, or medical illness; depression (assessed with the Geriatric Depression Scale);10 use of medications that affect cognition; and magnetic resonance imaging (MRI) contraindications.

Ten patients with AD (mean ± SD age, 74.8 ± 8.7 years) and 11 young control participants (mean ± SD age, 24.5 ± 3.7 years) were included for comparison of [11C]PiB uptake only. Young participants were recruited from the University of California, Berkeley, campus and the surrounding community via advertisements. Inclusion criteria were age of 20 to 30 years, normal performance on cognitive tests (≥2 SDs below age-, years of education-, and sex-adjusted means), MMSE score of 26 or higher, and Geriatric Depression Scale score less than 10. Exclusion criteria were identical to those for older controls.

Patients with AD were recruited from the Memory and Aging Center at the University of California, San Francisco, met the age criterion of 60 years or older, and volunteered for MRI at the University of California, San Francisco, and [11C]PiB PET at Lawrence Berkeley National Laboratory from October 31, 2005, to February 22, 2011. The clinical evaluation included a history and physical examination by a neurologist, a structured caregiver interview by a nurse, and a battery of neuropsychological tests.11 Clinical diagnosis was assigned by consensus at a multidisciplinary conference by investigators masked to [11C]PiB status, using standard research criteria.12 Patients with comorbid medical or psychiatric illnesses or other neurologic diagnoses were excluded. Apolipoprotein E E4 (ApoE4) carrier status was determined for 64 of 65 healthy older participants, 8 of 11 young participants, and 9 of 10 patients with AD.

This study was approved by the institutional review boards of all participating institutions, and all participants or their surrogates gave written informed consent.

COGNITIVE AND PHYSICAL ACTIVITY

Frequency of cognitive stimulation throughout life was assessed in healthy older individuals only using a previously reported 25-item interview in which participants were asked to report how often they engaged in common cognitively demanding activities that depend minimally on socioeconomic status, such as reading books or newspapers, writing letters or e-mails, going to the library, and playing games, at 5 age epochs: 6, 12, 18, and 40 years and the current age. Responses for each item were made using a 5-point frequency scale: 5, every day or almost every day; 4, several times a week; 3, several times a month; 2, several times a year; and 1, once a year or less.13 Because the number of test items varied slightly across the age epochs, 5 separate epoch means were calculated for each study participant so that the age epochs with more test items did not contribute disproportionately to the overall mean. We then created 3 composite scores that were used in subsequent analyses: past cognitive activity, which was an average of epoch means across ages 6, 12, 18, and 40 years; lifetime cognitive activity, which was an average across all 5 epoch means; and current cognitive activity, which was the average of interview items from the current epoch only.

Previous studies13 have described this instrument in detail and reported that the cognitive activity interview has high internal consistency and is positively associated with educational and cognitive performance. In this study, the test-retest correlation of the cognitive activity interview was 0.81 based on 41 cognitively normal older individuals who completed 2 consecutive annual evaluations that included the interview. This is similar to the test-retest correlation reported previously for this scale.13

Participants also completed a physical and leisure activity interview in which they indicated all physical and leisure activities (eg, cycling, walking, dancing, yoga) they participated in during a typical, recent 2-week period. A physical activity measurement (kilocalories burned during a recent 2-week period) was calculated by multiplying the time spent on the activity by an intensity index.14,15

NEUROPSYCHOLOGICAL TESTING

As described, healthy older controls completed an extensive neuropsychological battery, administered on average 0.37 years before or after PET (SD, 0.32 years) to screen for impaired cognition. Episodic memory was assessed by the immediate free recall portion of the California Verbal Learning Test (sum of 5 recall trials of the same 16-word list).16 To determine subjective memory function, participants were asked to rate their memory function compared with other people their age and compared with their memory ability 20 years ago, using a 4-point scale (1, better; 2, the same; 3, a bit worse; and 4, much worse).

STRUCTURAL MRI AND ANALYSIS

High-resolution structural MRIs were used to identify brain regions used for the [11C]PiB PET analysis. Structural MRIs in young and healthy older controls were conducted at the Lawrence Berkeley National Laboratory on a 1.5-T Magnetom Avanto System (Siemens Medical Systems) with a 12-channel head coil run in triple mode. The MRI session included an axial, T2-weighted attenuated inversion recovery scan (repetition time, 9730 milliseconds; echo time, 100 milliseconds; flip angle, 15°; 0.80 × 0.80 mm2 in plane resolution; and 3.00-mm thickness with no gap), which was used to screen for stroke, and 3 axial, T1-weighted, volumetric magnetization prepared rapid gradient-echo (MPRAGE) scans (repetition time, 2110 milliseconds; echo time, 3.58 milliseconds; inversion time, 1100 milliseconds; flip angle, 15°; 1.00 × 1.00 mm2 in plane resolution; and 1.00-mm thickness with 50% gap), which were averaged together and used to delineate brain regions for the [11C]PiB PET analysis.
For patients with AD, structural MRI was performed at the University of California, San Francisco. For 11 patients, scans were acquired coronally on a 1.5-T VISION System (Siemens Medical Systems) with a quadrature head coil (repetition time, 10 milliseconds; echo time, 7 milliseconds; flip angle, 15°; 1.00 × 1.00 mm² in plane resolution; and 1.40-mm section thickness with no gap), and for the remaining 6 participants they were acquired sagittally on a Bruker MedSpec +T System controlled by a Trio console with an 8-channel head coil (Siemens Medical Systems) (repetition time, 2300 milliseconds; echo time, 3.37 milliseconds; inversion time, 950 milliseconds; flip angle, 7°; 1.00 × 1.00 mm² in plane resolution; and 1.00-mm section thickness with no gap).

To identify regions of interest, MRIs were processed using FreeSurfer software, version 4.5.0 (http://surfer.nmr.mgh.harvard.edu/), as described previously. Briefly, for older controls with multiple MPRAGE images, scans were realigned and averaged to create a single high-contrast structural image. (For young controls and patients with AD, only a single T1-weighted MPRAGE image was acquired.) Regions relevant to PET processing were then derived in each participant’s native space.

To define the spatial transformation from each participant’s native space to MNI template space, the high-resolution structural scan was nonlinearly aligned to the standard MNI 152 brain using FNIRT, a nonlinear image registration tool (http://www.fmrib.ox.ac.uk/fsl/fnirt/). Resulting parameters were used to transform [11C]PiB PET image maps.

[11C]PiB PET IMAGING AND ANALYSIS

The [11C]PiB PET imaging was conducted at the Lawrence Berkeley National Laboratory on a Siemens ECAT EXACT HR PET scanner in 3-dimensional acquisition mode. Approximately 19 mCi of [11C]PiB was injected into an antecubital vein, and 90 minutes of dynamic acquisition frames were obtained (4 × 15 seconds, 8 × 30 seconds, 9 × 60 seconds, 2 × 180 seconds, 8 × 300 seconds, and 3 × 600 seconds). Data were realigned using the SPM8 software package (The MathWorks Inc), and distribution volume ratios were generated using Logan graphical analysis with frames corresponding to 35 to 90 minutes after injection and a gray matter–masked cerebellum reference region.22,23

A [11C]PiB index was derived for each participant representing the average of the mean distribution volume ratios from 4 large regions of interest that were defined using each participant’s native space structural MRIs: prefrontal cortex (all cortex anterior to the precentral sulcus), lateral temporal cortex (middle and superior temporal gyrus), parietal cortex (supramarginal gyrus, inferior and superior parietal lobules, and precuneus), and anterior and posterior cingulate gyrus.17

The [11C]PiB PET results presented in this study are not based on data corrected for partial volume effects, but the relationships between our primary variables of interest ([11C]PiB index and past cognitive activity) did not differ when partial volume–corrected data were used.

In addition to the region of interest analysis, [11C]PiB PET maps were transformed to MNI space (see the “Structural MRI and Analysis” subsection). To demonstrate the topography of the relationship between PiB uptake and cognitive activity, voxelwise correlations were performed on spatially normalized [11C]PiB distribution volume ratio maps with past cognitive activity as a regressor (and age, sex, and years of education as nuisance variables), evaluating results at P < .001 and a cluster size of 100 voxels, 2-tailed. These analyses were performed using permutation testing with FSL’s Randomise (http://www.fmrib.ox.ac.uk/fsl/randomise/index.html), which does not assume an underlying distribution of the data and thus accounts for the nonparametric nature of the [11C]PiB data.

RESULTS

Higher lifetime cognitive activity was significantly associated with lower cortical [11C]PiB uptake (P = .003, Spearman r = −0.37). To investigate the separate contributions of past and present cognitive activity, the lifetime mean cognitive activity score was subdivided into a past cognitive activity score (ages, 6–40 years; see the “Methods” section) and a current cognitive activity score.24 The relationship between higher current cognitive activity and lower [11C]PiB uptake was a nonsignificant trend (P = .09), but higher past cognitive activity was associated with lower [11C]PiB uptake (mean [SD] β = −1.73 ± 0.47; P < .001, accounting for age, sex, and years of education; Figure 1), and this association was unchanged by the addition of current episodic memory performance to the model (mean [SD] β = −1.84 [0.45], P < .001). Because it appeared to be driving the association with [11C]PiB, the past cognitive activity subscore was used in subsequent analyses.
In this study, we aimed to investigate the relationship between past cognitive activity and 
[11C]PiB uptake, a marker of amyloid burden, in patients with AD, young controls, and older controls. We divided the participants into past cognitive activity tertiles based on their activity scores, which were calculated as the average of activity scores across different age groups (6, 12, 18, and 40 years). The activity scores were based on the frequency of cognitive and physical activities reported by the participants during a recent 2-week period.

Table 1: Characteristics of the Patients With AD, Young Controls, and Older Controls, Divided Into Past Cognitive Activity Tertiles

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>AD Patients</th>
<th>Young Controls</th>
<th>All</th>
<th>Bottom Tertile</th>
<th>Middle Tertile</th>
<th>Top Tertile</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of study participants</td>
<td>10</td>
<td>11</td>
<td>65</td>
<td>22</td>
<td>22</td>
<td>21</td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td>3 (30)</td>
<td>6 (55)</td>
<td>42</td>
<td>15 (68)</td>
<td>12 (65)</td>
<td>15 (71)</td>
</tr>
<tr>
<td>ApoE4 carriers, No. (%)</td>
<td>6/9 (67)</td>
<td>5/8 (63)</td>
<td>19/64 (30)</td>
<td>8/21 (38)</td>
<td>4/22 (18)</td>
<td>7/21 (33)</td>
</tr>
<tr>
<td>ApoE4 allele frequency, %</td>
<td>0.44</td>
<td>0.31</td>
<td>0.16</td>
<td>0.23</td>
<td>0.09</td>
<td>0.17</td>
</tr>
<tr>
<td>[11C]PiB uptake</td>
<td>1.54 (0.24)</td>
<td>1.04 (0.24)</td>
<td>1.11</td>
<td>1.22 (0.23)</td>
<td>1.08 (0.08)</td>
<td>1.03 (0.06)</td>
</tr>
<tr>
<td>Age, y</td>
<td>74.8 (8.7)</td>
<td>24.5 (3.7)</td>
<td>76.1</td>
<td>76.3 (5.6)</td>
<td>76.0 (6.4)</td>
<td>76.2 (7.0)</td>
</tr>
<tr>
<td>Years of education</td>
<td>17.1 (2.8)</td>
<td>16.2 (1.9)</td>
<td>17.0</td>
<td>16.7 (2.3)</td>
<td>17.0 (2.2)</td>
<td>17.3 (1.8)</td>
</tr>
<tr>
<td>MMSE score</td>
<td>19.5 (8.0)</td>
<td>...</td>
<td>29.0</td>
<td>28.7 (1.5)</td>
<td>28.9 (1.4)</td>
<td>29.3 (0.7)</td>
</tr>
<tr>
<td>Depression score</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>MMSE score (maximum, 80)</td>
<td>...</td>
<td>...</td>
<td>55.4</td>
<td>(8.2)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Physical activity interview, kcal</td>
<td>...</td>
<td>...</td>
<td>4965</td>
<td>(3792)</td>
<td>3507 (3059)</td>
<td>4325 (2127)</td>
</tr>
<tr>
<td>Cognitive activity interview score</td>
<td>...</td>
<td>...</td>
<td>3.50</td>
<td>(0.63)</td>
<td>2.80 (0.43)</td>
<td>3.55 (0.17)</td>
</tr>
<tr>
<td>Past (maximum, 5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>3.93 (0.59)</td>
<td>3.51 (0.48)</td>
<td>3.98 (0.60)</td>
</tr>
<tr>
<td>Current (maximum, 5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>3.93 (0.59)</td>
<td>3.51 (0.48)</td>
<td>3.98 (0.60)</td>
</tr>
<tr>
<td>Lifetime (maximum, 5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>3.55 (0.58)</td>
<td>2.93 (0.39)</td>
<td>3.60 (0.23)</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer disease; ApoE4, apolipoprotein E4; MMSE, Mini-Mental State Examination; [11C]PiB, carbon-11-labeled Pittsburgh B Compound.

Table 2: Characteristics of the Patients With AD, Young Controls, and Older Controls, Divided Into Past Cognitive Activity Tertiles

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>AD Patients</th>
<th>Young Controls</th>
<th>All</th>
<th>Bottom Tertile</th>
<th>Middle Tertile</th>
<th>Top Tertile</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of study participants</td>
<td>10</td>
<td>11</td>
<td>65</td>
<td>22</td>
<td>22</td>
<td>21</td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td>3 (30)</td>
<td>6 (55)</td>
<td>42</td>
<td>15 (68)</td>
<td>12 (65)</td>
<td>15 (71)</td>
</tr>
<tr>
<td>ApoE4 carriers, No. (%)</td>
<td>6/9 (67)</td>
<td>5/8 (63)</td>
<td>19/64 (30)</td>
<td>8/21 (38)</td>
<td>4/22 (18)</td>
<td>7/21 (33)</td>
</tr>
<tr>
<td>ApoE4 allele frequency, %</td>
<td>0.44</td>
<td>0.31</td>
<td>0.16</td>
<td>0.23</td>
<td>0.09</td>
<td>0.17</td>
</tr>
<tr>
<td>[11C]PiB uptake</td>
<td>1.54 (0.24)</td>
<td>1.04 (0.24)</td>
<td>1.11</td>
<td>1.22 (0.23)</td>
<td>1.08 (0.08)</td>
<td>1.03 (0.06)</td>
</tr>
<tr>
<td>Age, y</td>
<td>74.8 (8.7)</td>
<td>24.5 (3.7)</td>
<td>76.1</td>
<td>76.3 (5.6)</td>
<td>76.0 (6.4)</td>
<td>76.2 (7.0)</td>
</tr>
<tr>
<td>Years of education</td>
<td>17.1 (2.8)</td>
<td>16.2 (1.9)</td>
<td>17.0</td>
<td>16.7 (2.3)</td>
<td>17.0 (2.2)</td>
<td>17.3 (1.8)</td>
</tr>
<tr>
<td>MMSE score</td>
<td>19.5 (8.0)</td>
<td>...</td>
<td>29.0</td>
<td>28.7 (1.5)</td>
<td>28.9 (1.4)</td>
<td>29.3 (0.7)</td>
</tr>
<tr>
<td>Depression score</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>MMSE score (maximum, 80)</td>
<td>...</td>
<td>...</td>
<td>55.4</td>
<td>(8.2)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Physical activity interview, kcal</td>
<td>...</td>
<td>...</td>
<td>4965</td>
<td>(3792)</td>
<td>3507 (3059)</td>
<td>4325 (2127)</td>
</tr>
<tr>
<td>Cognitive activity interview score</td>
<td>...</td>
<td>...</td>
<td>3.50</td>
<td>(0.63)</td>
<td>2.80 (0.43)</td>
<td>3.55 (0.17)</td>
</tr>
<tr>
<td>Past (maximum, 5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>3.93 (0.59)</td>
<td>3.51 (0.48)</td>
<td>3.98 (0.60)</td>
</tr>
<tr>
<td>Current (maximum, 5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>3.93 (0.59)</td>
<td>3.51 (0.48)</td>
<td>3.98 (0.60)</td>
</tr>
<tr>
<td>Lifetime (maximum, 5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>3.55 (0.58)</td>
<td>2.93 (0.39)</td>
<td>3.60 (0.23)</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer disease; ApoE4, apolipoprotein E4; MMSE, Mini-Mental State Examination; [11C]PiB, carbon-11-labeled Pittsburgh B Compound.

To determine whether the relationship between [11C]PiB and cognitive activity could be explained by any other variables, we examined a number of pairwise associations. We found that [11C]PiB was marginally inversely related to years of education (P = .052, Spearman r = −.24) but was not related to current episodic memory performance, physical activity, MMSE score, ApoE carrier status, or age. Past cognitive activity was associated with physical activity (P = .001, Spearman r = .40) and episodic memory (P = .04, Spearman r = .26) but not years of education, sex, depression, subjective memory ratings, or ApoE4 carrier status.

Because cognitive activity and physical activity were associated with one another, we performed a regression model with past cognitive activity, physical activity, and a cognitive activity × physical activity interaction term as independent variables (along with age, sex, and years of education) and log-transformed [11C]PiB as the dependent variable to determine whether cognitive activity was independently associated with [11C]PiB or whether this association could be explained by physical activity. Cognitive activity alone was a significant predictor of [11C]PiB uptake (P = .002).

Older controls were divided into tertiles based on past cognitive activity. We observed the expected differences in [11C]PiB across young controls, older controls, and patients with AD, with [11C]PiB levels lower in younger controls than older controls (P = .04) and higher in patients with AD than older or younger controls (P < .001) (Table 1 and Figure 2). Within older controls, the cognitive activity tertiles differed from one another with respect to [11C]PiB (P = .001) such that the lowest tertile had higher [11C]PiB uptake than the middle tertile (P = .04) and the top tertile (P = .001). The current physical activity interview scores were calculated by multiplying the time reported for each physical or leisure activity (eg, walking, cycling, dancing, or yoga) during a recent 2-week period by an intensity index for that activity.

Our data are consistent with the observation that participants in cognitively stimulating activities in early to middle age had lower [11C]PiB uptake than younger controls, which is consistent with the hypothesis that cognitive activity may protect against AD pathology. The differences in [11C]PiB uptake were noted across all age groups, suggesting that cognitive activity may have a protective effect against AD pathology from early to middle adulthood.
individuals with greater lifelong participation in complex mental activities showed less hippocampal atrophy, another biomarker of AD pathology.

An association between [11C]PiB uptake and memory performance has been reported in some studies but not others. We did not find evidence of this association, perhaps because participants were selected on the basis of intact cognition, thereby restricting the range of memory performance. Thus, our results do not bear directly on whether participation in these lifelong cognitive activities might also protect against the effects of accumulating Aβ through a mechanism of cognitive reserve. It is possible that cognitive activity could play a dual role in preventing the pathology and attenuating the neural response to this pathology.

Our cognitive activity measurement is likely just one of a variety of interrelated lifestyle factors that are difficult to quantify. Cognitive activity and (marginally) years of education were associated with [11C]PiB uptake (although cognitive activity and years of education were not related to one another), suggesting that these measurements may reflect a broader underlying tendency to engage in intellectual, occupational, social, and recreational activities. We also found that physical activity was associated with cognitive activity but not with [11C]PiB, but the addition of physical activity to the model did not reduce the association between cognitive activity and PiB, indicating that cognitive activity was the primary variable driving the association. Physical activity has been linked to Aβ previously, although this study differed from ours in that it assessed a 10-year exercise history of walking, jogging, or running, whereas the present study used a recent 2-week assessment of any physical or leisure activity. In addition, the time scale of the physical and cognitive activity indices are important in this study; our physical activity measure assessed current function, whereas the cognitive activity interview assessed lifelong cognitive engagement. The association between [11C]PiB and cognitive (but not physical) activity may thus reflect a time-sensitive neural process in which early- and middle-life practices have a greater influence on AD pathology than later-life practices.
Biologically plausible mechanisms could underlie the association we detected. Recent in vitro, animal, and human data indicate that neural activity regulates the secretion of Aβ. In addition, the cortical pattern of Aβ deposition overlaps with a set of highly interconnected networks that have been described as cortical hubs. These multimodal nodes, which include the posterior cingulate, lateral temporal and parietal, as well as medial and lateral prefrontal regions, are highly active during cognitive activity and rest and therefore may be susceptible to Aβ deposition. Although it is difficult to verify the association between increased neural activation and Aβ deposition in humans, it is conceivable that increased synaptic activity throughout the lifespan within this network of cortical hubs plays a role in the pathogenesis of AD later in life. Individuals who participate in a variety of cognitively stimulating activities during the lifespan may develop more efficient neural processing that results in less Aβ deposition. Supporting this idea, transgenic Aβ-expressing mice exposed to enriched environments deposit less Aβ than control animals.

Although the associations we report are cross-sectional, the pattern of the relationships suggests a temporal ordering of events such that cognitive activity (reflecting events occurring in early and middle life) precedes Aβ aggregation, which likely begins in middle life and precedes cognitive decline. Although the cognitive activity interview is a reliable and well-validated scale, it is based on self-report and could be biased. However, the specificity of the observed association with Aβ for past, but not current, cognitive activity seems to mitigate this concern. Furthermore, past cognitive activity was not associated with other factors that might be expected to reflect recall bias, such as subjective memory ratings or depression. Nevertheless, it remains possible that another unmeasured etiologic factor occurring early in life might both reduce the propensity to participate in cognitively stimulating activities and promote Aβ aggregation.

It is unlikely that our results reflect a single unitary cause of AD, which is a complex disease with many potential pathogenetic processes. Furthermore, cognitive activity is just one component of a complex set of lifestyle practices linked to AD risk that may be examined in future work. However, the present findings extend previous findings that link cognitive stimulation and AD risk (an indirect downstream effect of Aβ) by providing evidence that is consistent with a model in which cognitive stimulation is linked directly to the AD-related pathology itself.

Accepted for Publication: October 21, 2011.

Correspondence: Susan M. Landau, PhD, Helen Wills Neuroscience Institute, 118 Barker Hall, MC 3190, University of California, Berkeley, Berkeley, CA 94720-3190 (slandau@berkeley.edu).

Author Contributions: Study concept and design: Landau, Marks, Mormino, Rabinovici, Oh, Wilson, and Jagust. Acquisition of data: Mormino, Rabinovici, O’Neil, and Jagust. Analysis and interpretation of data: Landau, Marks, Mormino, O’Neil, and Jagust. Drafting of the manuscript: Landau, Mormino, Oh, and O’Neil.

References

19. Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometri-